Journal: Expert opinion on emerging drugs

Article Title: Emerging serine-threonine kinase inhibitors for treating ovarian cancer

doi: 10.1080/14728214.2019.1696773

Figure Lengend Snippet: Terms used for PubMed and ClinicalTrials.gov search.

Article Snippet: Triciribine phosphate , Prescient Therapeutics , CN1C2 = NC = NC3 = C2C(= CN3C4C (C(C(O4)COP(= O)(O)O)O)O)C(= N1)N , Combination with Carboplatin (C) , Recurrent, platinum resistant , Not specified , Phase II , AKT inhibitor.

Techniques:

Journal: Expert opinion on emerging drugs

Article Title: Emerging serine-threonine kinase inhibitors for treating ovarian cancer

doi: 10.1080/14728214.2019.1696773

Figure Lengend Snippet: Competitive environment characteristics of drugs with confirmed phase II/III activity for ovarian cancer are described in the table.

Article Snippet: Triciribine phosphate , Prescient Therapeutics , CN1C2 = NC = NC3 = C2C(= CN3C4C (C(C(O4)COP(= O)(O)O)O)O)C(= N1)N , Combination with Carboplatin (C) , Recurrent, platinum resistant , Not specified , Phase II , AKT inhibitor.

Techniques: Activity Assay, Mutagenesis

Journal: Expert opinion on emerging drugs

Article Title: Emerging serine-threonine kinase inhibitors for treating ovarian cancer

doi: 10.1080/14728214.2019.1696773

Figure Lengend Snippet: Clinical trials of STK inhibitors in active development for ovarian cancer active and completed clinical trials for drugs discussed in this review.

Article Snippet: Triciribine phosphate , Prescient Therapeutics , CN1C2 = NC = NC3 = C2C(= CN3C4C (C(C(O4)COP(= O)(O)O)O)O)C(= N1)N , Combination with Carboplatin (C) , Recurrent, platinum resistant , Not specified , Phase II , AKT inhibitor.

Techniques: Clinical Proteomics

Journal: The Journal of Clinical Investigation

Article Title: Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217

doi: 10.1172/JCI129249

Figure Lengend Snippet: (A) Immunohistochemical (IHC) staining of paraffin sections from the mammary glands of heterozygous Col1a1tm1Jae (COL+/–; n = 3) and WT (n = 3) mice using a phospho–histone H3–specific antibody. Selected mice were treated with the ZNF217/Akt inhibitor triciribine (TRIC; n = 3 each for WT and COL+/– mice). Scale bar: 50 μm. (B) Quantification of positive phospho–histone H3 staining from A expressed as the percentage of highly positive nuclei area per total epithelial area (n = 14–16). (C) qRT-PCR analysis for miR-203 using RNA isolated from the mammary glands of 10-week-old COL+/– mice and age-matched WT counterparts. Results are normalized to U6 RNA levels and plotted relative to WT (n = 4). (D) IHC staining of paraffin sections as in A using a ZNF217-specific antibody. Scale bar: 50 μm. (E) Quantification of positive ZNF217 staining from D expressed as the percentage of high positive staining in MECs (n = 15). (F) IHC staining of paraffin sections as in A using a phosphorylated Akt substrate–specific antibody. Selected mice were treated with triciribine as in A. Scale bar: 50 μm. (G) Quantification of positive phosphorylated Akt substrate staining from F expressed as the percentage of high positive staining in MECs (n = 12–15). Data are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 by 2-tailed unpaired Student’s t test (C and E) or Kruskal-Wallis test followed by Dunn’s multiple-comparison test (B and G).

Article Snippet: Triciribine (APExBIO, catalog A8541) was diluted in DMSO and administered by intraperitoneal injection to 8-week-old Col1a1 tm1Jae mice at a dosage of 1 mg/kg, 5 times per week, for a total of 2 weeks.

Techniques: Immunohistochemical staining, Immunohistochemistry, Staining, Quantitative RT-PCR, Isolation, Comparison

Journal: British Journal of Clinical Pharmacology

Article Title: AKT in cancer: new molecular insights and advances in drug development

doi: 10.1111/bcp.13021

Figure Lengend Snippet: Ongoing clinical trials involving AKT inhibitors as registered on clinicaltrials.gov as of October 2015

Article Snippet: PTX‐200 , Prescient Therapeutics , Triciribine , PH domain (AKT) inhibitor , I/II , Advanced or metastatic HER2‐negative BC with paclitaxel, doxorubicin and cyclophosphamide.

Techniques: Protease Inhibitor